Iatrogenic Cushing’s Syndrome Due to Intranasal Usage of Ophthalmic Dexamethasone: A Case Report

Iatrogenic Cushing’s syndrome (ICS) is caused by exogenous corticosteroid administration with suppression of the hypothalamic–pituitary–adrenal axis. It has been commonly described with oral and topical steroid use, but scarce reports have documented intranasal steroid usage as the etiology in infancy. In this article, we describe a case of a 4-month-old infant who developed ICS after 6 weeks of intranasal dexamethasone ophthalmic solution administration for nasal obstruction. To our knowledge, this is the youngest patient reported with ICS due to intranasal use of a prescribed dose of an ophthalmic steroid. His hypothalamic–pituitary–adrenal axis recovered fully 4.5 months after steroid discontinuation. Because of the small body surface area and supine position during administration, infants are particularly susceptible to ICS. Given that intranasal steroids are commonly prescribed to infants and children for a variety of diagnoses, this case highlights the risks inherent in the use of intranasal steroid drops, particularly in young infants, for both adrenal suppression and linear growth deceleration, even with short-term use. Close monitoring of these patients’ height and weight should occur while on steroid treatment, with every effort made to decrease or discontinue steroid use when possible.

[1]  Y. Berkun,et al.  Iatrogenic Cushing Syndrome due to Intranasal Dexamethasone , 2015, Clinical pediatrics.

[2]  V. Baş,et al.  Iatrogenic Cushing's syndrome due to overuse of topical steroid in the diaper area. , 2014, Journal of Tropical Pediatrics.

[3]  M. Koçak,et al.  Cushing’s syndrome: hidden risk in usage of topical corticosteroids , 2014, Journal of pediatric endocrinology & metabolism : JPEM.

[4]  A. N. Onyiriuka,et al.  Iatrogenic cushing's syndrome in children following nasal steroid , 2014, The Pan African medical journal.

[5]  S. Mukhopadhyay,et al.  Iatrogenic Cushing’s Syndrome Following Short-Term Intranasal Steroid Use , 2012, Journal of clinical research in pediatric endocrinology.

[6]  Z. Aycan,et al.  Iatrogenic Cushing syndrome due to nasal steroid drops , 2012, European Journal of Pediatrics.

[7]  Ş. Ergin,et al.  Two Cases of Cushing’s Syndrome Due to Overuse of Topical Steroid in the Diaper Area 1 , 2008, Pediatric dermatology.

[8]  A. Alikaşifoğlu,et al.  Inappropriate Use of Potent Topical Glucocorticoids in Infants , 2007, Journal of pediatric endocrinology & metabolism : JPEM.

[9]  M. Donaldson,et al.  Cushing's syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids , 2002, Archives of disease in childhood.

[10]  Y. Greenman,et al.  Low‐dose (1 μg) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo–pituitary–adrenal axis function: sensitivity, specificity and accuracy in comparison with the high‐dose (250 μg) test , 2000 .

[11]  Y. Greenman,et al.  Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. , 2000, Clinical endocrinology.

[12]  S. Grinspoon,et al.  Clinical review 62: Laboratory assessment of adrenal insufficiency. , 1994, The Journal of clinical endocrinology and metabolism.

[13]  R. Kimmerle,et al.  Iatrogenic Cushing's syndrome due to dexamethasone nasal drops. , 1985, The American journal of medicine.